Geron is betting that more older people will mean more blood cancers, which could lift demand for its new cancer medicine and support stronger profits over time. The catch is that almost everything depends on this one drug and a smooth rollout, so any stumble in competition, safety, or overseas access could quickly change the story.Read more
Geron is betting that its new cancer-focused treatment can win over doctors faster than many expect, pushing it into wider use and opening up new markets outside the US. But the whole story leans heavily on one expensive drug, so pricing pushback, tougher rules, or stronger rivals could quickly change the outlook.Read more
Geron’s growth story hinges on one cancer drug, but tougher drug-pricing rules, slower approvals, and rising competition could make it harder to keep expanding into new patients and countries. At the same time, strong early uptake and wider insurance coverage could keep momentum going—if the launch continues to deliver.Read more
No trending discussion available.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
